Opus Genetics, Inc.
IRDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeOpus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of. The company carries a $354.9M market cap, placing it firmly in the small-cap category. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Market Cap
$354.9M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-6.21
EPS (TTM)
$-1.31
EPS (Fwd)
$-0.70
ROE
-7594.6%
ROA
-46.8%
Cash
$60.0M
Total Debt
$1.2M
Free CF
—
52W Change
300.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $60.0M in cash comfortably exceeding the $1.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. ROE of -7594.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $39.9M (2022) to $14.2M (2025), a 64% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IRD.